Location: Warminster , PA 18974 +1 (215)-443-7000

Our Mission

 

i3 Pharmaceuticals will excel in the development, manufacture and supply of complex solid oral generic products. We are a US-based manufacturer dedicated to bringing specialty pharmaceuticals to market that establish value for our customers and instill the confidence of quality and value in patients.

  • Why we exist: US-based development and manufacturing of solid oral dose generic products
  • What makes us different: we use technology and know-how to solve difficult formulations
  • What is our value: high-quality generic products that increase patients’ affordability and confidence in therapy.
  • What is our inspiration: insight, ingenuity and integrity

Capabilities/Facilities

 
Facility

In 2015, i3 Pharmaceuticals acquired a 150,000 sqft facility in Warminster, PA. After substantial capital investment, the facility was commissioned in 2017.

 
Capabilities

Product development, manufacturing, packaging and testing, Pilot Plant sized to promote efficient and reliable scale-up, Variety of capacities in blending,

 
Our Expertise

Solid Oral Dosage Forms, Sustained Release (ER/SR/DR) Formulations, Poorly Soluble Drugs, Unstable Molecules, Potent Compounds, Bioavailability Enhancement Technically Challenging Products

 

News & Updates

 
2024
  • January - Launched Isosorbide Dinitrate and Hydralazine Hydrochloride 20mg/37.5mg tablets into US Market
 
Learn More
2023
  • March - Successful FDA cGMP Inspection and five-product Prior Approval Inspection
  • October - Launched Posaconazole DR 100mg tablets into US Market.
  • November - Launched Maraviroc 150mg and 300mg tablets into US Market.
  • December - Launched Guanfacine 1mg and 2mg tablets into US Market
 
Learn More
2022
  • February - Launched Selegiline HCl 5mg tablets into US Market. First product commercialized in the i3 label.
  • October - Launched Ranolazine 500mg and 1000mg extended-release tablets into US Market
 
Learn More